文献速递MDS 与骨髓增殖性肿瘤白血病

MDS向继发性白血病进展的遗传学

Genetics of progression from MDS to secondary leukemia.
PubMed 文献 · Blood · 2020-01-01

本文综述二代测序技术推动下对骨髓增生异常综合征(MDS)向急性髓系白血病(AML)进展遗传学的认识。MDS与继发性AML共享多种基因及功能类别突变,证实二者为疾病连续体;进展几乎均伴克隆演化,测序监测肿瘤负荷与克隆演化优于原始细胞计数,并讨论将分子遗传数据纳入诊断、分类和监测的优势。

要点

  • MDS与继发性AML共享染色质修饰、DNA甲基化、RNA剪接、黏连蛋白复合体、转录因子、细胞信号和DNA损伤等基因突变,属疾病连续体。
  • MDS与继发性AML中突变基因频率的差异表明进展过程中突变获得顺序并非随机。
  • 几乎每例疾病进展均伴克隆演化,通常表现为具有独特突变集的亚克隆扩增或出现。

核心结论

  • MDS与继发性AML在遗传上相关,共享多种基因及功能类别突变,证实二者为疾病连续体。
  • 测序监测肿瘤负荷与克隆演化优于原始细胞计数,后者低估肿瘤负荷,并可能允许在临床恶化前早期检测疾病进展。
  • 由于测序在临床中日益常规,需持续研究以确定不同临床情境下的最佳检测方法及如何利用数据改善MDS和继发性AML患者的结局。

研究设计与样本

  • 综述,聚焦MDS向继发性AML进展的遗传学及将分子遗传数据纳入诊断、分类和监测的优势。

主要发现

  • MDS与继发性AML细胞携带许多相同基因及功能类别的突变,包括染色质修饰、DNA甲基化、RNA剪接、黏连蛋白复合体、转录因子、细胞信号和DNA损伤。
  • MDS与继发性AML中突变基因频率的差异表明进展过程中突变获得顺序并非随机。
  • 几乎每例疾病进展均与克隆演化相关,通常定义为具有独特突变集的亚克隆扩增或出现。

局限性

  • 原文指出需持续研究以确定不同临床情境下的最佳检测方法及如何利用数据改善患者结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our understanding of the genetics of acute myeloid leukemia (AML) development from myelodysplastic syndrome (MDS) has advanced significantly as a result of next-generation sequencing technology. Although differences in cell biology and maturation exist between MDS and AML secondary to MDS, these 2 diseases are genetically related. MDS and secondary AML cells harbor mutations in many of the same genes and functional categories, including chromatin modification, DNA methylation, RNA splicing, cohesin complex, transcription factors, cell signaling, and DNA damage, confirming that they are a disease continuum. Differences in the frequency of mutated genes in MDS and secondary AML indicate that the order of mutation acquisition is not random during progression. In almost every case, disease progression is associated with clonal evolution, typically defined by the expansion or emergence of a subclone with a unique set of mutations. Monitoring tumor burden and clonal evolution using sequencing provides advantages over using the blast count, which underestimates tumor burden, and could allow for early detection of disease progression prior to clinical deterioration. In this review, we outline advances in the study of MDS to secondary AML progression, with a focus on the genetics of progression, and discuss the advantages of incorporating molecular genetic data in the diagnosis, classification, and monitoring of MDS to secondary AML progression. Because sequencing is becoming routine in the clinic, ongoing research is needed to define the optimal assay to use in different clinical situations and how the data can be used to improve outcomes for patients with MDS and secondary AML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Menssen AJ, Walter MJ. Genetics of progression from MDS to secondary leukemia. Blood. 2020. PMID: 32430504. doi:10.1182/blood.2019000942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。